GLP 1 ulcerative colitis records study ties the drugs to higher remission at 12 weeks

People with GLP 1 ulcerative colitis treatment in a West Virginia records study were far more likely to reach symptom remission at 12 weeks than matched patients who did not take the drugs, a paper in Inflammatory Bowel Diseases reports. The 150 patients had started liraglutide or semaglutide for diabetes or weight, not for their colitis. Remission was 66.7% against 25.3% in 150 controls. Weight loss did not explain the gap. The design, though, cannot rule out that healthier or more engaged patients were the ones who got and kept the drugs.

What the West Virginia team compared

Budoor Alqinai, Swapna Gayam and Jennifer Hadam-Veverka of West Virginia University searched the electronic health records of one tertiary academic health system for adults with ulcerative colitis seen between 2022 and 2024. They kept those who started liraglutide or semaglutide for a metabolic reason, such as type 2 diabetes or obesity, and who stayed on the drug for at least 12 weeks. That gave 150 treated patients. Each was paired with a patient with ulcerative colitis who had never taken a GLP 1 receptor agonist and who looked similar at baseline, giving 150 controls. Disease activity was scored at 4, 8 and 12 weeks with the partial Mayo score, which rests on stool frequency, rectal bleeding and a physician global rating rather than on a camera.

The main outcome was symptomatic remission at week 12, defined as a partial Mayo score of 2 or less with no rectal bleeding. The authors then used multivariable logistic regression to adjust the odds of remission for immunomodulator use and baseline disease severity. A smaller group of patients also had an endoscopy during the study window, which allowed a separate look at the lining of the colon itself. The paper was received on 18 May, accepted on 27 July and published online on 21 August 2026, and wider coverage followed in October. Only the abstract is freely available. It does not give the funding source, the exact matching variables or how many patients had endoscopy, so those details remain unknown here.

GLP 1 ulcerative colitis remission at 12 weeks

The gap opened early and kept growing. At 4 weeks, 34.7% of treated patients were in symptomatic remission against 15.3% of controls. At 8 weeks the figures were 54.7% and 18.0%, and at 12 weeks 66.7% and 25.3%. Mean partial Mayo scores in the GLP 1 group fell from 5.8 at baseline to 2.1 by week 12, while the control group's figure was reported at 4.6, a much smaller shift from the same starting point. After adjustment for immunomodulators and baseline severity, GLP 1 therapy remained linked to remission, with an adjusted odds ratio of 5.90 and a 95% confidence interval from 3.52 to 9.86. In plain terms, treated patients had close to six times the odds of reaching remission at week 12.

In plain terms, treated patients had close to six times the odds of reaching remission at week 12.

One result stands out for anyone wondering whether lighter patients simply felt better. Weight loss was not independently associated with remission in the authors' model, which they take as a hint that any benefit may run through something other than the scale. That idea fits laboratory work on gut hormones. Mouse experiments reported on this site found that gut glucagon like peptides helped protect the intestine from an immune attack, and GLP 1 receptors sit on several immune and gut lining cells. Still, the abstract does not test any mechanism, and a missing link with weight in a modest sample is weak evidence against weight as a factor. Inflammation markers such as calprotectin are not reported in the abstract either.

Semaglutide against liraglutide and the endoscopy subset

Within the treated group, semaglutide users did better than liraglutide users, with 72.5% in remission at 12 weeks against 60.0% and an odds ratio of 1.77 that only just reached significance, with a P value of .04. The split between the two drugs is not given in the abstract, and the patients were not randomised to one or the other. Semaglutide is the newer and more potent agent, and it usually brings more weight loss, so prescribing habits, timing and patient type could all lie behind the difference. The authors call the edge modest. It is a reason to ask the question in a trial, not a reason to pick one drug over the other for colitis today.

The endoscopy data matter because symptoms can improve while the bowel lining stays inflamed. In the subset of patients who had an endoscopy, 58% of the GLP 1 group showed endoscopic remission against 38% of controls, and 69% against 47% showed some mucosal improvement. These numbers point the same way as the symptom scores. But the abstract does not say how many people were scoped, why they were scoped or whether the endoscopists knew who was taking a GLP 1 drug. Patients who get an endoscopy in routine care are often those whose doctors want to check a change, so the subset may not represent the full group. That makes the endoscopic result supportive rather than decisive.

Why a records study cannot settle it

The biggest weakness is how patients entered the treated group. Everyone in it had to stay on the drug for at least 12 weeks, so people who stopped early, perhaps because of nausea or a flare, were left out by design. Patients who receive and continue a metabolic drug may also differ from controls in access to care, follow up and attention to their health. Matching and regression reduce such differences only for factors that were measured. Symptom scores were taken from clinical notes in an unblinded setting. And this is one health system. A recent systematic review of 14 studies found that nearly all the evidence on these drugs in inflammatory bowel disease comes from records analyses like this one.

The study still adds a clear signal to the GLP 1 ulcerative colitis record. Its effect size is large compared with most observational work in the field, and the authors suggest a possible adjunct role for GLP 1 drugs in ulcerative colitis, especially in patients who also have metabolic disease. Testing that needs a randomised trial with endoscopic and biomarker end points, run against placebo on top of standard colitis treatment. For comparison, the oral peptide icotrokinra in a phase 2 trial was tested that way in 252 adults. Until such a trial exists, GLP 1 drugs remain treatments for diabetes and obesity that may be safe to continue in colitis, not colitis drugs. The journal abstract online gives the full figures.

Conclusion

This single centre study links GLP 1 ulcerative colitis treatment, given for metabolic reasons, to higher symptom remission at 12 weeks and better endoscopic findings in a subset, independent of weight loss. The effect is large, but selection of patients who stayed on the drug, unblinded scoring and an unknown endoscopy sample limit what it can show. A randomised trial is the needed next step.

Source Alqinai B, Gayam S, Hadam-Veverka J. GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study. Inflammatory Bowel Diseases, 21 August 2026. DOI 10.1093/ibd/izag167

Amino Weekly reports research. It is not medical advice and never gives doses.